Table 1.
Baseline characteristics
| No MWF | MWF | P | |
|---|---|---|---|
| N | 84 | 32 | |
| Age, yrs | 62.3 ± 13.7 | 63.8 ± 11.9 | 0.29 |
| Male, n (%) | 51 (61) | 27 (84) | 0.02 |
| Height, m | 1.68 ± 0.09 | 1.74 ± 0.09 | 0.02 |
| Weight, Kg | 83.4 ± 18.6 | 83.3 ± 12.6 | 0.97 |
| NYHA class | 0.20 | ||
| I | 4 (5) | 3 (9) | |
| II | 15 (18) | 8 (25) | |
| III | 47 (56) | 11 (34) | |
| IV | 9 (11) | 5 (16) | |
| Unknown | 9 (11) | 5 (16) | |
| Diabetes mellitus, n (%) | 13 (16) | 7 (24) | 0.42 |
| Hypertension, n (%) | 18 (22) | 5 (17) | 0.61 |
| Atrial fibrillation, n (%) | 15 (18) | 8 (24) | 0.44 |
| Medication, n (%) | |||
| Loop diuretics | 62 (81) | 26 (89) | 0.47 |
| ACE-I or ARB | 77 (97) | 27 (90) | 0.31 |
| Beta-blockers | 51 (65) | 20 (66) | 1.00 |
| Aldosterone antagonists | 36 (46) | 10 (35) | 0.29 |
| Systolic blood pressure, mmHg | 124.3 ± 20.5 | 119.6 ± 23.1 | 0.38 |
| Diastolic blood pressure, mmHg | 71.5 ± 11.9 | 71.7 ± 13.8 | 0.96 |
| QRS duration (ms) | 144 (28) | 149 (32) | 0.48 |
ACE-I angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers